Laboratory evidence of PD-1 upregulation on T cells in PML patients [8] led to the off-label use of checkpoint inhibitors in the therapy of PML patients where no other option was available to reinvigorate antiviral immunity. This evidence concerns the gene PDCD1 and progressive multifocal leukoencephalopathy.